Dulaglutide Added to Sodium-Glucose Cotransporter-2 Inhibitors Improves Glycemic Control in Patients with Type 2 Diabetes

February 23, 2018. This double-blind, parallel-arm, placebo-controlled, phase 3b study assessed the superiority of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide vs placebo when added to a sodium-glucose cotransporter-2 (SLGT-2) inhibitor. Patients (N=424) with uncontrolled type 2 diabetes (T2D) were randomized to receive dulaglutide 1.5 mg, dulaglutide 0.75 mg, or placebo, with or without metformin. At 24 weeks, patients receiving either dulaglutide dose had greater reductions in A1C vs placebo (dulaglutide 1.5 mg least squares mean [LSM]: -1.34%; dulaglutide 0.75 mg: -1.21%; placebo: -0.54%; P<0.0001 for both groups vs placebo). The LSM differences for dulaglutide 1.5 mg and 0.75 mg were -0.79% (95% confidence interval [CI]: -0.97 to -0.61) and -0.66% (95% CI: -0.84 to -0.49), respectively (P<0.0001 for both). Treatment-emergent adverse events in the dulaglutide group were consistent with the drug’s established safety profile; for example, gastrointestinal adverse events were more frequent with dulaglutide vs placebo. These results indicate that dulaglutide added to SGLT-2 inhibitors significantly improves glycemic control in patients with T2D. You can read the abstract here.